<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36507615</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2042-6984</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>International forum of allergy &amp; rhinology</Title><ISOAbbreviation>Int Forum Allergy Rhinol</ISOAbbreviation></Journal><ArticleTitle>Use of platelet-rich plasma for COVID-19-related olfactory loss: a randomized controlled trial.</ArticleTitle><Pagination><StartPage>989</StartPage><EndPage>997</EndPage><MedlinePgn>989-997</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/alr.23116</ELocationID><Abstract><AbstractText Label="INTRODUCTION">The current study evaluated the use of platelet-rich plasma (PRP), an autologous blood product with supraphysiologic concentrations of growth factors, in the treatment of prolonged coronavirus disease 2019 (COVID-19)-related smell loss.</AbstractText><AbstractText Label="METHODS">This multi-institutional, randomized controlled trial recruited patients with COVID-19 who had objectively measured smell loss (University of Pennsylvania Smell Identification Test [UPSIT]&#xa0;&#x2264;&#xa0;33) between 6 and 12 months. Patients were randomized to three intranasal injections of either PRP or sterile saline into their olfactory clefts. The primary outcome measure was change in Sniffin' Sticks score (threshold, discrimination, and identification [TDI]) from baseline. The secondary end point measures included responder rate (achievement of a clinically significant improvement, &#x2265;5.5 points TDI), change in individual TDI olfaction scores, and change in subjective olfaction via a visual analog scale.</AbstractText><AbstractText Label="RESULTS">A total of 35 patients were recruited and 26 completed the study. PRP treatment resulted in a 3.67-point (95% CI: 0.05-7.29, p&#xa0;=&#xa0;0.047) greater improvement in olfaction compared with the placebo group at 3 months and a higher response rate (57.1% vs 8.3%, odds ratio 12.5 [95% exact bootstrap confidence interval, 2.2-116.7]). There was a greater improvement in smell discrimination following PRP treatment compared with placebo but no difference in smell identification or threshold. There was no difference in subjective scores between PRP and placebo. No adverse effects were reported.</AbstractText><AbstractText Label="CONCLUSION">Olfactory function following COVID-19 can improve spontaneously after 6 months and can improve to a greater extent with PRP injection. These data build on the promise of PRP to be a safe potential treatment option for patients with COVID-19-related smell loss, and larger-powered studies will help further assess its efficacy.</AbstractText><CopyrightInformation>&#xa9; 2022 ARS-AAOA, LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Carol H</ForeName><Initials>CH</Initials><Identifier Source="ORCID">0000-0003-1934-4922</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology, Head and Neck Surgery, University of California, San Diego School of Medicine, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Sophie S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, Head and Neck Surgery, University of California, San Diego School of Medicine, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Hung-Fu C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, Head and Neck Surgery, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Yifei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, Head and Neck Surgery, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khanwalkar</LastName><ForeName>Ashoke R</ForeName><Initials>AR</Initials><Identifier Source="ORCID">0000-0001-9960-7758</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology, Head and Neck Surgery, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thai</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9459-5476</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology, Head and Neck Surgery, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Zara M</ForeName><Initials>ZM</Initials><Identifier Source="ORCID">0000-0003-2072-982X</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology, Head and Neck Surgery, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08 DC019956</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08DC019956</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int Forum Allergy Rhinol</MedlineTA><NlmUniqueID>101550261</NlmUniqueID><ISSNLinking>2042-6976</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086582" MajorTopicYN="N">Anosmia</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000857" MajorTopicYN="Y">Olfaction Disorders</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012903" MajorTopicYN="N">Smell</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053657" MajorTopicYN="Y">Platelet-Rich Plasma</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">PRP</Keyword><Keyword MajorTopicYN="N">anosmia</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">olfaction</Keyword><Keyword MajorTopicYN="N">persistent olfactory dysfunction</Keyword><Keyword MajorTopicYN="N">platelet-rich plasma</Keyword><Keyword MajorTopicYN="N">post COVID syndrome</Keyword><Keyword MajorTopicYN="N">smell loss</Keyword><Keyword MajorTopicYN="N">therapeutics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>12</Day><Hour>11</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36507615</ArticleId><ArticleId IdType="mid">NIHMS1854454</ArticleId><ArticleId IdType="pmc">PMC9877663</ArticleId><ArticleId IdType="doi">10.1002/alr.23116</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tan BKJ, Han R, Zhao JJ, et&#xa0;al. Prognosis and persistence of smell and taste dysfunction in patients with covid&#x2010;19: meta&#x2010;analysis with parametric cure modelling of recovery curves. BMJ. 2022;378:e069503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9326326</ArticleId><ArticleId IdType="pubmed">35896188</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel ZM, Holbrook EH, Turner JH, et&#xa0;al. International consensus statement on allergy and rhinology: olfaction. Int Forum Allergy Rhinol. 2022;12(4):327&#x2010;680.</Citation><ArticleIdList><ArticleId IdType="pubmed">35373533</ArticleId></ArticleIdList></Reference><Reference><Citation>Said M, Luong T, Jang SS, Davis ME, DeConde AS, Yan CH. Clinical factors associated with lower health scores in COVID&#x2010;19&#x2013;related persistent olfactory dysfunction. Int Forum Allergy Rhinol. 2022;12(10):1242&#x2010;1253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9011709</ArticleId><ArticleId IdType="pubmed">35032409</ArticleId></ArticleIdList></Reference><Reference><Citation>Burges Watson DL, Campbell M, Hopkins C, Smith B, Kelly C, Deary V. Altered smell and taste: anosmia, parosmia and the impact of long Covid&#x2010;19. PLoS One. 2021;16(9):e0256998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8462678</ArticleId><ArticleId IdType="pubmed">34559820</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaira LA, Gessa C, Deiana G, et&#xa0;al. The effects of persistent olfactory and gustatory dysfunctions on quality of life in long&#x2010;COVID&#x2010;19 patients. Life. 2022;12(2):141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8878431</ArticleId><ArticleId IdType="pubmed">35207429</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster KE, O'Byrne L, MacKeith S, Philpott C, Hopkins C, Burton MJ. Interventions for the prevention of persistent post&#x2010;COVID&#x2010;19 olfactory dysfunction. Cochrane Database Syst Rev. 2022;9(9):CD013877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9443936</ArticleId><ArticleId IdType="pubmed">36063364</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel ZM, Wise SK, DelGaudio JM. Randomized controlled trial demonstrating cost&#x2010;effective method of olfactory training in clinical practice: essential oils at uncontrolled concentration. Laryngoscope Investig Otolaryngol. 2017;2(2):53&#x2010;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5527365</ArticleId><ArticleId IdType="pubmed">28894822</ArticleId></ArticleIdList></Reference><Reference><Citation>Damm M, Pikart LK, Reimann H, et&#xa0;al. Olfactory training is helpful in postinfectious olfactory loss: a randomized, controlled, multicenter study. Laryngoscope. 2014;124(4):826&#x2010;831.</Citation><ArticleIdList><ArticleId IdType="pubmed">23929687</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechner M, Liu J, Counsell N, et&#xa0;al. The COVANOS trial &#x2013; insight into post&#x2010;COVID olfactory dysfunction and the role of smell training. Rhin. 2022;60(3):188&#x2010;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">35901492</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaylac&#x131; A, Azak E, &#xd6;nal A, Akt&#xfc;rk DR, Karadenizli A. Effects of classical olfactory training in patients with COVID&#x2010;19&#x2010;related persistent loss of smell. Eur Arch Otorhinolaryngol. 2022;Jul 29:1&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9335450</ArticleId><ArticleId IdType="pubmed">35904631</ArticleId></ArticleIdList></Reference><Reference><Citation>Pires &#xcd;de AT, Steffens ST, Mocelin AG, et&#xa0;al. Intensive olfactory training in post&#x2010;COVID&#x2010;19 patients: a multicenter randomized clinical trial. Am J Rhinol Allergy. 2022:36(6):780&#x2010;787.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9309586</ArticleId><ArticleId IdType="pubmed">35866202</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen TP, Patel ZM. Budesonide irrigation with olfactory training improves outcomes compared with olfactory training alone in patients with olfactory loss. Int Forum Allergy Rhinol. 2018;8(9):977&#x2010;981.</Citation><ArticleIdList><ArticleId IdType="pubmed">29901865</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S, Lee JJ, Perrin A, et&#xa0;al. Efficacy and safety of saline nasal irrigation plus theophylline for treatment of COVID&#x2010;19&#x2010;related olfactory dysfunction: the SCENT2 Phase 2 randomized clinical trial. JAMA Otolaryngol Head Neck Surg. 2022;148(9):830&#x2010;837.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9264240</ArticleId><ArticleId IdType="pubmed">35797024</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasiri H, Rouhani N, Salehifar E, Ghazaeian M, Fallah S. Mometasone furoate nasal spray in the treatment of patients with COVID&#x2010;19 olfactory dysfunction: a randomized, double blind clinical trial. Int Immunopharmacol. 2021;98:107871.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8196319</ArticleId><ArticleId IdType="pubmed">34147912</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan CH, Rathor A, Krook K, et&#xa0;al. Effect of omega&#x2010;3 supplementation in patients with smell dysfunction following endoscopic sellar and parasellar tumor resection: a multicenter prospective randomized controlled trial. Neurosurgery. 2020;87(2):E91&#x2010;E98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7360874</ArticleId><ArticleId IdType="pubmed">31950156</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaira LA, Hopkins C, Petrocelli M, et&#xa0;al. Efficacy of corticosteroid therapy in the treatment of long&#x2010; lasting olfactory disorders in COVID&#x2010;19 patients. Rhin. 2021;59(1):21&#x2010;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">33290446</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Stadio A, D'Ascanio L, Vaira LA, et&#xa0;al. Ultramicronized palmitoylethanolamide and luteolin supplement combined with olfactory training to treat post&#x2010;COVID&#x2010;19 olfactory impairment: a multi&#x2010;center double&#x2010;blinded randomized placebo&#x2010;controlled clinical trial. CN. 2022:20(10):2001&#x2010;2012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9886808</ArticleId><ArticleId IdType="pubmed">35450527</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerner D, Garvey K, Arrighi&#x2010;Allisan A, et&#xa0;al. Letter to the editor: study summary &#x2010; randomized control trial of omega&#x2010;3 fatty acid supplementation for the treatment of COVID&#x2010;19 related olfactory dysfunction. Trials. 2020;21(1):942.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7681177</ArticleId><ArticleId IdType="pubmed">33225989</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Liu X, Wang Y. Evaluation of platelet&#x2010;rich plasma therapy for peripheral nerve regeneration: a critical review of literature. Front Bioeng Biotechnol. 2022;10:808248.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8923347</ArticleId><ArticleId IdType="pubmed">35299637</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan CH, Mundy DC, Patel ZM. The use of platelet&#x2010;rich plasma in treatment of olfactory dysfunction: a pilot study. Laryngoscope Investig Otolary. 2020;5(2):187&#x2010;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7178450</ArticleId><ArticleId IdType="pubmed">32337347</ArticleId></ArticleIdList></Reference><Reference><Citation>Mavrogeni P, Kanakopoulos A, Maihoub S, Krasznai M, Szirmai A. Anosmia treatment by platelet rich plasma injection. Int Tinnitus J. 2017;20(2):102&#x2010;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">28452719</ArticleId></ArticleIdList></Reference><Reference><Citation>Steffens Y, Le Bon SD, Lechien J, et&#xa0;al. Effectiveness and safety of PRP on persistent olfactory dysfunction related to COVID&#x2010;19. Eur Arch Otorhinolaryngol. 2022:279(12):5951&#x2010;5953.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9336533</ArticleId><ArticleId IdType="pubmed">35904632</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasak AG, Yigit O, Araz Server E, Durna Dastan S, Gul M. The effectiveness of platelet&#x2010;rich plasma in an anosmia&#x2010;induced mice model. Laryngoscope. 2018;128(5):E157&#x2010;E162.</Citation><ArticleIdList><ArticleId IdType="pubmed">29243256</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan AM, Lee J, Rammaha T, et&#xa0;al. Natural trajectory of recovery of COVID&#x2010;19 associated olfactory loss. Am J Otolaryngol. 2022;43(5):103572.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9355743</ArticleId><ArticleId IdType="pubmed">35969913</ArticleId></ArticleIdList></Reference><Reference><Citation>London B, Nabet B, Fisher AR, White B, Sammel MD, Doty RL. Predictors of prognosis in patients with olfactory disturbance. Ann Neurol. 2008;63(2):159&#x2010;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">18058814</ArticleId></ArticleIdList></Reference><Reference><Citation>Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G. &#x2018;Sniffin&#x2019; sticks&#x2019;: olfactory performance assessed by the combined testing of odour identification, odor discrimination and olfactory threshold. Chem Senses. 1997;22(1):39&#x2010;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">9056084</ArticleId></ArticleIdList></Reference><Reference><Citation>Parzen M, Lipsitz S, Ibrahim J, Klar N. An estimate of the odds ratio that always exists. J Comput Graph Statist. 2002;11(2):420&#x2010;436.</Citation></Reference><Reference><Citation>Tutar B, Ekincioglu E, Karaketir S, et&#xa0;al. The impact of platelet&#x2010;rich fibrin (PRF) on olfactory function and pain after septoplasty operations. Eur Arch Otorhinolaryngol. 2020;277(4):1115&#x2010;1120.</Citation><ArticleIdList><ArticleId IdType="pubmed">32048028</ArticleId></ArticleIdList></Reference><Reference><Citation>Goljanian Tabrizi A, Asadi M, Mohammadi M, Abedi Yekta A, Sohrabi M. Efficacy of platelet&#x2010;rich plasma as an adjuvant therapy to endoscopic sinus surgery in anosmia patients with sinonasal polyposis: a randomized controlled clinical trial. Med J Islam Republ Iran. 2021;35:156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8932217</ArticleId><ArticleId IdType="pubmed">35341080</ArticleId></ArticleIdList></Reference><Reference><Citation>Prajapati DP, Shahrvini B, Said M, Srinivas S, DeConde AS, Yan CH. Assessment of patient recognition of coronavirus disease 2019 (COVID&#x2010;19)&#x2010;associated olfactory loss and recovery: a longitudinal study. Int Forum Allergy Rhinol. 2021;11(11):1529&#x2010;1537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8222875</ArticleId><ArticleId IdType="pubmed">34096193</ArticleId></ArticleIdList></Reference><Reference><Citation>Holbrook EH, Rebeiz L, Schwob JE. Office&#x2010;based olfactory mucosa biopsies. Int Forum Allergy Rhinol. 2016;6(6):646&#x2010;653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4921276</ArticleId><ArticleId IdType="pubmed">26833660</ArticleId></ArticleIdList></Reference><Reference><Citation>Amable PR, Carias RBV, Teixeira MVT, et&#xa0;al. Platelet&#x2010;rich plasma preparation for regenerative medicine: optimization and quantification of cytokines and growth factors. Stem Cell Res Ther. 2013;4(3):67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706762</ArticleId><ArticleId IdType="pubmed">23759113</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>